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Abstract
Background: Colistin and tigecycline have both been shown good in vitro activity among multi-drug resistant
Acinetobacter baumannii (MDRAB). A comparative study of colistin versus tigecycline for MDRAB pneumonia is lacking.
Methods: The study enrolled adults with MDRAB pneumonia admitted to intensive care units at a referral medical
center during 2009–2010. Since there were no standardized minimum inhibitory concentration (MIC) interpretation
criteria of tigecycline against A. baumannii, MIC of tigecycline was not routinely tested at our hospital. During the study
periods, MIC of colistin was not routinely tested also. We consider both colistin and tigecycline as definite treatments of
MDRAB pneumonia. Patients who received tigecycline were selected as potential controls for those who had received
colistin. We performed a propensity score analysis, by considering the criteria of age, gender, underlying diseases, and
disease severity, in order to match and equalize potential prognostic factors and severity in the two groups.
Results: A total of 294 adults with MDRAB pneumonia were enrolled, including 119 who received colistin and 175 who
received tigecycline. We matched 84 adults who received colistin with an equal number of controls who received
tigecycline. The two well matched cohorts share similar characteristics: the propensity scores are colistin: 0.37 vs.
tigecycline: 0.37, (P = .97); baseline creatinine (1.70 vs. 1.81, P = .50), and the APACHE II score (21.6 vs. 22.0, P = .99). The
tigecycline group has an excess mortality of 16.7% (60.7% vs. 44%, 95% confidence interval 0.9% – 32.4%, P = .04). The
excess mortality of tigecycline is significant only among those with MIC >2 μg/mL (10/12 vs. 37/84, P = .01), but not for
those with MIC ≦ 2 μg/mL (4/10 vs. 37/84, P = .81).
Conclusions: Our data disfavors the use of tigecycline-based treatment in treating MDRAB pneumonia when tigecycline
and colistin susceptibilities are unknown, since choosing tigecycline-based treatment might result in higher mortality.
The excess mortality of tigecycline-based group may be related to higher MIC of tigecycline (> 2 μg/mL). Choosing
tigecycline empirically for treating MDRAB pneumonia in the critical setting should be cautious.
Keywords: Acinetobacter baumannii, Pneumonia, Colistin, Tigecycline, Mortality, Nephrotoxicity
* Correspondence: whsheng@ntu.edu.tw
1Department of Internal Medicine, National Taiwan University Hospital, No. 7
Chung-Shan South Road, Taipei 100, Taiwan
Full list of author information is available at the end of the article
© 2014 Chuang et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Chuang et al. BMC Infectious Diseases 2014, 14:102
http://www.biomedcentral.com/1471-2334/14/102
Background
Healthcare-associated infections caused by Acinetobacter
baumannii are increasing among patients in intensive
care units (ICU) [1,2]. These infections are associated
with a high mortality and a prolonged length of hospital
stay [2]. Pneumonia is the most common clinical syn-
drome [3]. However, due to the emerging multi-drug
resistance among A. baumannii isolates, the treatment
choice for multi-drug resistant A. baumannii (MDRAB)
related infection is limited [4].
Colistin and tigecycline have been shown to have good
in vitro activity against A. baumannii pneumonia iso-
lates, even in carbapenem-resistant isolates [5,6]. In fact,
there have been successful experiences at using colistin
in treating MDRAB pneumonia [7,8], and colistin is rec-
ommended as a treatment option for pneumonia caused
by MDRAB [9]. However, poor pulmonary penetration
[10] and renal toxicity are the major concerns [8,11].
Tigecycline also presents good in vitro activity against
MDRAB isolates [6], and several studies have revealed
acceptable clinical responses of tigecycline for MDRAB
pneumonia [6,12,13]. Though there are no available
minimum inhibitory concentration (MIC) interpretation
breakpoints of tigecycline against A. baumannii accord-
ing to the criteria of the Clinical and Laboratory Stan-
dards Institute (CLSI) or the European Committee on
Antimicrobial Susceptibility Testing (EUCAST) [2], tige-
cycline have been suggested as an alternative drug of
choice in treating MDRAB pneumonia [14]. In spite of
all this, a comparative study of colistin versus tigecycline
for MDRAB pneumonia is lacking [6,8,15]. The aim of
the current study is to compares the effectiveness and
the adverse effects of colistin-based versus tigecycline-
based therapy in treating MDRAB pneumonia.
Methods
Study population
This is a retrospective study conducted among patients
admitted to the ICU at the National Taiwan University
Hospital (NTUH). NTUH is a 2,200-bed teaching hos-
pital located in northern Taiwan that provides both pri-
mary and tertiary medical care. This study was approved
by NTUH IRB committee.
Patients with MDRAB pneumonia and treated with
colistin or tigecycline were enrolled in this study from
January 2009 through December 2010. MDRAB was de-
fined as A. baumannii, which showed non-susceptibility
to ≥ 1 agent in ≥ 3 antimicrobial categories [16]. Pneumo-
nia was defined based on a prospective surveillance by the
microbiology lab and infection controls at NTUH [17]. A
patient with a pneumonia must have either a new onset
of purulent sputum, a change in the character of sputum,
rales or dullness to percussion from a physical examination
of the chest, chest radiographic examinations indicating
new or progressive infiltrates, consolidation, cavitation, or
pleural effusion and MDRAB isolated from the blood,
bronchoscopic bronchial brushing, lavage or suitable spu-
tum (defined as > 25 polymorphonuclear neutrophil and <
10 squamous epithelial cells per low power field). We used
qualitative culture through the study. Ventilator-associated
pneumonia (VAP) is defined as pneumonia developed 48 h
or longer after mechanical ventilation is given by means of
endotracheal intubation or tracheostomy. Patients are fur-
ther classified by ventilator status: early-onset VAP (< 5 d
of ventilation) or late-onset VAP (≥ 5 d of ventilation).
NTUH restricts the prescription of colistin or tigecyc-
line to infectious disease physicians. In the circumstance
of MDRAB infection, the prescriptions are limited to cul-
ture proven MDRAB, which showed non-susceptibility to
ampicillin/sulbactam and the following anti-pseudomonas
antibiotics, included cephalosporins, extended-spectrum
penicillins, carbapenems, aminoglycosides, and fluoroqui-
nolones. Since there were no MIC interpretation criteria
of tigecycline against A. baumannii, MIC of tigecycline
was not routinely tested at our hospital. During the study
periods, MIC of colistin was not routinely tested also.
Therefore, we consider both colistin and tigecycline as
definite treatments of MDRAB pneumonia [2]. The dose
of colistin (Colimycin injection, TTY Biopharm Co., Ltd.,
Taipei, Taiwan) was colistin base activity (CBA) 2.5–5 mg/
kg/day in 2–3 divided doses (2 million units or 160 mg
colistin methanesulfonate equivalent to 66.8 mg CBA).
The dose of tigecycline was a 100 mg loading, followed by
50 mg every 12 hours.
This study excluded patients under the age of 18 years
or with incomplete medical records. We also excluded
patients with concomitant infection, such as methicillin
resistant Staphylococcus aureus or Pseudomonas aerugi-
nosa. When patients had multiple episodes of MDRAB
pneumonia and were treated with colistin or tigecycline,
only the first episode was included.
Microbiological studies
This study identified A. baumannii by biochemical
methods [18] and determined antimicrobial susceptibility
by the disk diffusion method for gentamicin, amikacin, cip-
rofloxacin, levofloxacin, cefepime, ceftazidime, ticarcillin/
clavulanate, meropenem, and ampicillin/sulbactam accord-
ing to CLSI criteria [19]. We performed MICs of colistin
by agar dilution methods according to CLSI criteria [19].
Lastly, MICs of tigecycline were determined by agar dilu-
tion methods (BBL, BD Diagnostic Systems, Sparks, MD),
with isolates of MIC ≦ 2 μg/mL were considered as being
susceptible [20].
Data collection
We collected demographic data, underlying diseases, and
the concomitant infections by a retrospective chart review,
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recorded regimens of antimicrobial combination, and
evaluated the severity of pneumonia by the Acute
Physiology and Chronic Health Evaluation (APACHE)
II score [21]. The outcomes for evaluation are in-
hospital mortality and nephrotoxicity. In patients with
normal renal function, nephrotoxicity was defined as a
doubling of baseline serum creatinine compared with
treatment initiation, or a reduction in the calculated
creatinine clearance (CLCr) of ≥ 50%. In patients with
a pre-existing renal dysfunction, nephrotoxicity was
defined as an increase of > 50% of the baseline creatin-
ine level compared with the value at treatment initi-
ation, a decrease of ≥ 20% of calculated serum CLCr
from the baseline, or a decline in renal function that
required renal replacement therapy [7,22]. Combin-
ation therapy was defined as at least 3 days of concur-
rent use of the antimicrobial agent other than colistin
or tigecycline.
Statistical analysis
We calculated the mean and standard deviation (SD) for
continuous variables and percentages for categorical var-
iables. We then compared the associations between the
clinical presentations of colistin and tigecycline treat-
ments using Student’s t test or Fisher’s exact test. A two-
sided p-value ≤ .05 was considered significant.
Since there may be significant baseline characteristic
differences between the colistin and tigecycline groups,
we used propensity score matching to balance the baseline
predictors for colistin or tigecycline use and mortality
[23]. Propensity score matched analysis provides quasi-
experimental design, which compared the outcome
between two similar groups [24]. We estimated the prob-
ability of patients receiving colistin rather than tigecycline
treatment with a logistic regression model, using their
baseline characteristics before enrollment as variables.
The fitted model was established by a stepwise variable se-
lection procedure, with the significance levels for stay set
to 0.2. Age and gender were forced to be considered in the
final model. We conducted all matching on a one-to-one
basis without replacement, set the caliper at 0.25, and
chose the size of the caliper to be 0.0603.
For the matched cohorts, this study examined post-
match balancing by using the paired t test or McNemar’s
chi-square test [24]. We then calculated the risk differ-
ence (RD) in outcome, which included mortality, and
nephrotoxicity, between the colistin group and the
tigecycline group, or the average treatment effect of the
treated (ATT). The data were analyzed with Stata soft-
ware, version 12 (StataCorp, College Station, Texas). We
used R 2.14.2 software (R Foundation for Statistical
Computing, Vienna, Austria) with the Package Matching




A total of 294 ICU-admitted patients, who were found
to have MDRAB pneumonia and were treated with colis-
tin or tigecycline, were enrolled during the study period.
Among the patients, 119 received colistin and 175
received tigecycline. Table 1 presents the demographic
characteristics and underlying diseases of the 294 pa-
tients with MDRAB pneumonia. There were no signifi-
cant differences among the different treatment groups
for age, APACHE II score, and duration of treatment.
However, patients treated with tigecycline had signifi-
cantly lesser underlying malignancies (1.1% vs. 28.6%,
P < .001). The most common combination regimen used
was carbapenem combination (34/294, 11.6%).
There were no significant differences of underlying
chronic kidney diseases (23.5% vs. 17.7%, P = .24) and
baseline creatinine (1.66 vs. 1.81, P = .40) before treatment
between the colistin and tigecycline groups. However,
patients treated with colistin suffered from a significantly
higher rate of nephrotoxicity (10.1% vs. 3.4%, P = .03).
There was no significant mortality rate difference between
the colistin and tigecycline groups (49.6% vs. 58.9%,
P = .12). There was no significant mortality difference be-
tween carbapenem with the colistin combination (n = 15)
and colistin without carbapenem combination (n = 104)
(46.7% vs. 50.0%, P = .81). There was also no significant
mortality difference between carbapenem with the tigecyc-
line combination (n = 19) and tigecycline without carba-
penem combination (n = 156) (42.1% vs. 60.9%, P = .12).
Propensity score matching analysis
We performed a multiple variables logistic analysis to
determine the significant independent variables associ-
ated with the choice of colistin rather than tigecycline
(Table 2). The factors associated with using colistin were
male, better baseline creatinine, insulin use, and under-
lying malignancy. The large number of differences among
the independent variables in the colistin and tigecycline
groups did not permit a definitive assessment of the effect
on the outcome. Accordingly, we employed a propensity
matching analysis to control for the effect of the numer-
ous confounders.
We matched 84 pairs of patients. There were no suit-
able tigecycline treatment controls for 35 unmatched
colistin treated cases. After matching, the two groups of
patients showed no significant differences of potential
prognostic factors and severity of illness between them
(Table 3). The propensity scores were colistin: 0.370 vs.
tigecycline: 0.370, (P = .97); underlying malignancy (2.4%
vs. 2.4%, P = 1.00); and insulin use (23.8% vs. 25%, P = .85).
163 cases had positive sputum cultures of A. baumannii,
among them 118 sputum samples were from tracheo-
bronchial aspirate. 36 cases had positive bronchoscopic
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bronchial lavage culture. The mean time (± SD) elapsed
between Acinetobacter isolation and the beginning of
antibiotics of tigecycline or colistin group is 1.9 (± 1.8)
and 2 (± 1.5) days, respectively (P = .72). There were
three (one Chryseobacterium indologenes, one Escheri-
chia coli, and one Enterobacter aerogenes) polymicrobial
infections in tigecycline and four (one C. indologenes,
one E. coli, one Enterobacter cloacae, and one Klebe-
siella pneumoniae) in colistin group (P = .71). In patient
without renal dysfunction, the mean dose of colistin
used was CBA 3.0 (±0.8) mg/Kg/day. All the distribu-
tions of the estimated propensity scores were well-
balanced after matching (Figure 1). We saw a significant
mortality difference between the colistin and tigecycline
groups (44.1% vs. 60.7%), and the tigecycline group had
a significant excess mortality (RD 16.7%, 95% confi-
dence interval (C.I.) 0.9% – 32.4%, P = .04). The excess
mortality remained significant even after being adjusted
by propensity score, age, gender, and a combination of
carbapenem use (adjusted RD 16.4%, 95% C.I. 0.9% –
31.8%, P = .04) (Table 4). The colistin group had a
higher rate of nephrotoxicity (9.5% vs. 2.4%, P = .05).
The excess nephrotoxicity remained significant even
after being adjusted by propensity score (adjusted RD
7.4%, 95% C.I. 1.2% – 13.6%, P = .02).
The MIC50 and MIC90 of colistin were 1 and 2 μg/mL,
respectively. All tested isolates were susceptible to colistin.
Among patients who were treated with tigecycline, only
22 have isolates available for tigecycline MIC testing. The
MIC50 and MIC90 of tigecycline were 2 and 8 μg/mL, re-
spectively. The post-hoc analysis analyzing the mortality
showed that the excess mortality of tigecycline is signifi-
cant among those with MIC >2 mg/mL (10/12 vs. 37/84,
Table 1 Clinical and demographic characteristics of patients with multidrug resistant Acinetobacter baumannii
pneumonia treated with colistin or tigecycline
Characteristics Total N = 294 Colistin N = 119 Tigecycline N = 175 p- value
Age 63.8 (18.5) 63.7 (19.5) 63.8 (17.9) .95
Male 198 (67.3) 86 (72.3) 112 (64) .16
APACHE II score 22.5 (9.1) 22.8 (9.3) 22.3 (8.9) .68
Length of hospital stay before enrollment 32.0 (36.9) 33.2 (45.9) 31.2 (29.4) .64
Underlying diseases
Cardiovascular disease 47 (16.0) 17 (14.3) 30 (17.1) .63
Diabetes mellitus 84 (28.6) 33 (27.7) 51 (29.1) .90
Insulin use 63 (21.4) 28 (23.5) 35 (20) .47
Chronic kidney disease 59 (20.1) 28 (23.5) 31 (17.7) .24
Liver cirrhosis 13 (4.4) 4 (3.4) 9 (5.1) .57
Chronic pulmonary disease 30 (10.2) 15 (12.6) 15 (8.6) .33
Malignancy 36 (12.2) 34 (28.6) 2 (1.1) <.001
Autoimmune 16 (5.4) 5 (4.2) 11 (6.3) .60
Operation history 140 (47.6) 51 (42.9) 89 (50.9) .19
Combination therapy
Aminoglycoside 4 (1.4) 1 (0.8) 3 (1.7) .65
Carbapenem 34 (11.6) 15 (12.6) 19 (10.9) .65
Sulbactam 10 (3.4) 2 (1.7) 8 (4.6) .21
Baseline creatinine (mg/dL) 1.75 (1.47) 1.66 (1.43) 1.81 (1.50) .40
Duration of treatment 13.7 (12.5) 14.6 (13.7) 13.1 (11.6) .31
Follow-up duration 32.4 (31.5) 33.1 (30.9) 31.9 (32.0) .75
APACHE II, acute physiology and chronic health evaluation II.
Table 2 Logistic model for prediction of colistin rather






Age (year) 0.99 0.98 – 1.01 .69
Male 1.83 1.02 – 3.31 .04
Baseline creatinine (mg/dL) 0.76 0.57 – 1.01 .06
Chronic kidney
disease × Baseline creatinine 1.42 1.09 – 1.84 .01
Insulin use 1.55 0.82 – 2.93 .18
Malignancy 40.43 9.31 – 175.52 <.001
Estimated area under the ROC curve = 0.74.
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P = .01), but not for those with MIC ≦2 mg/mL (4/10 vs.
37/84, P = .81).
We rechecked the result of the propensity score match-
ing by a different matching scenario - the overfitted model
- which means all baseline factors before colistin or tige-
cycline use were considered in the logistic regression
model without stepwise selection. The results were simi-
lar. There was excess mortality of tigecycline (RD 19.7%,
95% C.I. 2.8% – 36.6%, P = .02), and the colistin group had
a significantly higher nephrotoxicity (RD 9.8%, 95% C.I.
1.1% – 18.6%, P = .03).
Discussion
We found a significantly higher mortality rate in the
tigecycline-based group and a higher rate of nephrotox-
icity in the colistin-based group among the well-matched
cohort. Post-hoc analysis showed that the mortality dif-
ference was noted in those with higher tigecycline MIC
(> 2μg/mL).
There are concerns over tissue binding of colistin,
poor colistin concentration in the lungs [10], and con-
versely tigecycline is concentrated in tissues, including
lung parenchyma [25]. However, there were several
meta-analysis showed excess overall mortality of tigecyc-
line in the pooled analysis of different infection [26–28].
The higher mortality might be due to increased supe-
rinfections and more adverse events in the tigecycline
groups [28], and an increased risk of death especially
among patients with VAP [29]. The other reason for a
significant treatment outcome difference may be partly
due to colistin exhibiting even better in vitro activity to
MDRAB [5]. In a previous study, Anthony et al. sug-
gested that tigecycline MIC values in A. baumannii iso-
lates may predict a clinical outcome [13]. Since our study
is a retrospective design, not all isolates had post-hoc MIC
testing. However, among the 104 preserved MDRAB iso-
lates, the colistin susceptibility rate was 100%, whereas
Table 3 Clinical and demographic characteristics of the
matched patients with multidrug resistant Acinetobacter






Age 63.8 (19.8) 63.5 (17.7) .92
Male 63 (75) 65 (77.4) .67
APACHE II score 21.6 (9.4) 22.0 (8.8) .99
Ventilator-associated pneumonia 58 (69.1) 60 (71.4) .74
Early onset VAP 6 (10.3) 4 (6.7) .38
Late onset VAP 52 (90.0) 56 (93.3)
Length of hospital stay before
enrollment
29.5 (33.7) 29.0 (30.1) .92
Length of ICU stay before
enrollment
20.2 (29.6) 18.5 (17.9) .56
Duration of treatment 14.0 (11.2) 12.9 (9.3) .51
Cardiovascular disease 15 (17.9) 15 (17.9) 1.00
Diabetes mellitus 24 (28.6) 27 (32.1) .59
Insulin use 20 (23.8) 21 (25) .85
Chronic kidney disease 22 (26.2) 22 (26.2) 1.00
Liver cirrhosis 2 (2.4) 4 (4.8) .41
Chronic pulmonary disease 8 (9.5) 8 (9.5) 1.00
Malignancy 2 (2.4) 2 (2.4) 1.00
Autoimmune 3 (3.6) 5 (6.0) .48
Operation history 40 (47.6) 45 (53.6) .44
Combination therapy
Aminoglycoside 1 (1.2) 2 (2.4) .56
Carbapenem 9 (10.7) 9 (10.7) 1.00
Sulbactam 1 (1.2) 3 (3.6) .32
Baseline creatine (mg/dL) 1.70 (1.40) 1.81 (1.60) .50
Propensity score 0.370 (0.130) 0.370 (0.131) .97
APACHE II, acute physiology and chronic health evaluation II; ICU, intensive

































Figure 1 Boxplot comparing the distribution of the logit model
of the estimated propensity scores (a) before and (b) after
matching patients receiving colistin with those
receiving tigecycline.
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the tigecycline susceptibility rate was only 50.0%. Though
tigecycline is concentrated in tissues, including lung
parenchyma, the concentration in epithelial lining fluid is
relatively low, with Cmax only 0.37 μg/mL, especially
compared to high MICs of tigecycline to A. baumannii
[25]. Though, while a high dose of tigecycline achieves a
higher Cmax, and might have better clinical efficacy [30],
high dose of tigecycline was not practiced at NTUH.
Recent study revealed that previous colistin dosage used
might be under dosing, which may possibly underestimate
the effectiveness of colistin in our cohort [31].
Combination therapy for MDRAB infection is contro-
versial. The combination of tigecycline with carbapenem
showed a comparable outcome than tigecycline mono-
therapy [12], while the combination of colistin with car-
bapenem showed a less favorable outcome than colistin
monotherapy [32]. According to Taiwanese regulations
(Regulations for National Health Insurance Reimburse-
ment), only few cases in out cohort had received tigecyc-
line or colistin combination therapy. Although our study
did not support the effectiveness of combination therapy
for MDRAB pneumonia, further large sample sized
prospective studies are warrant to illustrate the issue.
Colistin presented nephrotoxicity in around 6% of treated
patients [8]. However, in the meta-analysis of the two arms
study, Florescu et al. reported no significant higher rates
of nephrotoxicity in the colistin group than that in the
comparator group (Odds ratio 1.14, 95% C.I. 0.59 – 2.20,
P = .69). The difference may be due to the fact that the
baseline characteristics of the colistin and comparator
groups might be different especially in the observational
studies, but they were not adjusted in the meta-analysis.
In our study we showed borderline significant excess
nephrotoxicity of 7.1% of the colistin group compared to
tigecycline group (P = .05) for the baseline characteristic
comparable cohorts. Thus, for patients with predisposing
factors such as nephrotoxic drugs, chronic kidney dis-
eases, and hypovolemia, we should carefully monitor the
renal function during colistin use [11].
This study has several limitations. First, the majority
of the patients were diagnosed using qualitative sputum
culture, which might result in over-diagnosis of pneu-
monia. Hence, the difference of the effectiveness be-
tween tigecycline and colistin might be underestimated.
Second, there are difficulties inherent in the design of
any retrospective matched cohort study. We may have
missed some unobserved confounders that were unbal-
anced, even though the fitness of our prediction models
appear to be good (area under ROC: 0.74), and the result
is robust between different matching scenarios. In order
to avoid any possible misclassification bias in the re-
trospective design, a hard end point - mortality - is used
rather than clinical improvement. Third, since there
were no MIC interpretation criteria of tigecycline against
A. baumannii [2], our microbiology lab had no routine
antimicrobial susceptibility test of tigecycline. Thus not
all isolates had tigecycline susceptibility tested. Lastly, in
our lab, the MIC testing of colistin and tigecycline were
uniformly performed using agar dilution. The result of
broth microdilution might be affected by whether fresh
medium was used or Oxyrase was added, but agar dilu-
tion might not [33,34]. However, limited study showed
that the MIC obtained by agar dilution is lower than that
obtained by broth dilution techniques [33].
Conclusions
In patients with possible nephrotoxic factors, their renal
function during colistin use should be carefully monitored.
Our data disfavors the use of tigecycline-based treatment in
treating MDRAB pneumonia when tigecycline and colistin
susceptibilities are unknown, since choosing tigecycline-
based treatment might result in higher mortality. The ex-
cess mortality of tigecycline-based group may be related to
higher MIC of tigecycline (> 2 μg/mL). There is an urgent
need to establish the interpretation criteria of tigecycline
for MDRAB infection. The effectiveness of tigecycline use
in those with low tigecycline MIC in the era of emerging
MDRAB warrants further study.
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